HighTide Therapeutics

Rockville, United States Founded: 2011 • Age: 15 yrs
Developer of small molecule based therapeutics for the treatment of liver, gastrointestinal, and metabolic disorders

About HighTide Therapeutics

HighTide Therapeutics is a company based in Rockville (United States) founded in 2011.. HighTide Therapeutics has raised $107 million across 2 funding rounds from investors including CITIC, TCM Health Care and Yuexiu Capital. The company has 70 employees as of December 31, 2024. HighTide Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, Ironwood Pharma, Nimbus Therapeutics, Adocia and Altimmune, among others.

  • Headquarter Rockville, United States
  • Employees 70 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Hightide Therapeutics Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0 (USD)
    0
    as on Dec 31, 2024
  • Net Profit
    $-53.3 M (USD)
    60.12
    as on Dec 31, 2024
  • EBITDA
    $-61.27 M (USD)
    -4.72
    as on Dec 31, 2024
  • Total Equity Funding
    $107 M (USD)

    in 2 rounds

  • Latest Funding Round
    $107 M (USD), Series C

    Jan 05, 2023

  • Investors
    CITIC

    & 5 more

  • Employee Count
    70

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of HighTide Therapeutics

HighTide Therapeutics is a publicly listed company on the HKEX with ticker symbol 2511 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: HKEX · Ticker: 2511 . Sector: Health technology · Hong Kong
People of HighTide Therapeutics
Headcount 50-200
Employee Profiles 7
Employee Profiles
People
Liping Liu
Founder, CEO & CSO
People
Tianwei
Vice President, Discovery Research
People
Gwen Melincoff
Chief Business Advisor
People
Wan-Jen Yang
Director Of Biology

Unlock access to complete

Teams

Funding Insights of HighTide Therapeutics

HighTide Therapeutics has successfully raised a total of $107M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $107 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series C — $107.0M
  • First Round
  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2023 Amount Series C - HighTide Therapeutics Valuation Tcmhealthcare
Dec, 2020 Amount Series B - HighTide Therapeutics Valuation CITIC Securities , Cowin Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in HighTide Therapeutics

HighTide Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include CITIC, TCM Health Care and Yuexiu Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Yuexiu Capital is engaged in financial services and asset management.
Founded Year Domain Location
-
Founded Year Domain Location
TCM Health Care is focused on Traditional Chinese Medicine therapies.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by HighTide Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - HighTide Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Hightide Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of HighTide Therapeutics

HighTide Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Ironwood Pharma, Nimbus Therapeutics, Adocia and Altimmune, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Biologics are developed for cardio-metabolic and liver diseases.
domain founded_year HQ Location
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
domain founded_year HQ Location
Therapeutics for diabetes and obesity treatment are developed.
domain founded_year HQ Location
Vaccines for infectious diseases and solid tumors are developed.
domain founded_year HQ Location
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Hightide Therapeutics

Frequently Asked Questions about HighTide Therapeutics

When was HighTide Therapeutics founded?

HighTide Therapeutics was founded in 2011 and raised its 1st funding round 9 years after it was founded.

Where is HighTide Therapeutics located?

HighTide Therapeutics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.

Is HighTide Therapeutics a funded company?

HighTide Therapeutics is a funded company, having raised a total of $107M across 2 funding rounds to date.

How many employees does HighTide Therapeutics have?

As of Dec 31, 2024, the latest employee count at HighTide Therapeutics is 70.

What does HighTide Therapeutics do?

Developer of small molecule based therapeutics for the treatment of liver, gastrointestinal, and metabolic disorders. The companys lead product candidate HTD-1801 used for the treatment of primary sclerosing cholangitis, NAFLDNASH, and hypercholesterolemia. Other products of the company include HTD4010 used for the treatment of acute pancreatitis, HTD1804 for obesiry, HTD1805 for metabolic disease, and HTD2802 for IBD.

Who are the top competitors of HighTide Therapeutics?

HighTide Therapeutics's top competitors include Ironwood Pharma, Nimbus Therapeutics and Adocia.

Is HighTide Therapeutics publicly traded?

Yes, HighTide Therapeutics is publicly traded on HKEX under the ticker symbol 2511.

Who are HighTide Therapeutics's investors?

HighTide Therapeutics has 6 investors. Key investors include CITIC, TCM Health Care, Yuexiu Capital, Hongde Fund Management, and Cowin Capital.

What is HighTide Therapeutics's ticker symbol?

The ticker symbol of HighTide Therapeutics is 2511 on HKEX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available